(NASDAQ: VRTX) Vertex Pharmaceuticals's forecast annual revenue growth rate of 9.04% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.01%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 12.06%.
Vertex Pharmaceuticals's revenue in 2026 is $12,951,600,000.On average, 35 Wall Street analysts forecast VRTX's revenue for 2026 to be $3,428,082,890,154, with the lowest VRTX revenue forecast at $3,273,931,984,362, and the highest VRTX revenue forecast at $3,567,275,073,180. On average, 33 Wall Street analysts forecast VRTX's revenue for 2027 to be $3,796,980,205,824, with the lowest VRTX revenue forecast at $3,481,579,339,368, and the highest VRTX revenue forecast at $4,087,027,304,880.
In 2028, VRTX is forecast to generate $4,278,448,248,750 in revenue, with the lowest revenue forecast at $3,704,692,492,488 and the highest revenue forecast at $4,794,650,953,014.